1V-LSD (1-valeryl-D-lysergic acid diethylamide), also known as Valerie, is a psychotropic substance and psychedelic research chemical.1V-LSD is an analogue of LSD as well as an artificial derivative of natural lysergic acid, which occurs in ergot alkaloids. 1V-LSD was sold online until a 2022 amendment to the German NpSG, which controls 1P-LSD and now 1cP-LSD, 1V-LSD, and several other lysergamides, went into effect.
As with other N-acylated LSD derivatives, 1V-LSD is thought to act as a prodrug for LSD but may also act as a weak partial agonist at the 5-HT2A receptor.
A head-twitch response assay in mice revealed that 1V-LSD has a similar potency to 1P-LSD and 1cP-LSD, as well as behavioral effects that are similar to these structural analogs.
1V-LSD is the condensation product of valeric acid (pentanoic acid) and LSD, with the valeroyl group substituted on the NH position of the indole moiety. Ehrlich’s reagent is used to detect the presence of an indole moiety, which is the chemical backbone of the lysergamide and ergoline molecules. However, as with other N-acylated lysergamides, 1V-LSD reacts very slowly to Ehrlich reagent and may not give reliable results if the reagent is not fresh.
1V-LSD is classified as a Schedule 1 drug in the United States under the Federal Analogue Act.
Since March 2nd, 2022, 1V-LSD has been under investigation in Sweden and may soon become controlled.
1V-LSD was placed under legal control in South Korea on a temporary but renewable basis in July 2022.
In September 2022, a change to the NpSG prohibited the sale of 1V-LSD in Germany. The ban never took effect because of an interpunctation error in the finalised NpSG. The law was amended in March 2023 to prohibit 1V-LSD.